Ocrelizumab trial results

Two phase III studies of a potential new injected disease modifying drug for relapsing remitting MS show that it "significantly reduced" relapses, new lesions and the build up of disability compared to Rebif. The manufacturer plans to submit the drug for licensing next year. A phase III trial in primary progressive MS is due to report later this year. Reuters Roche press release Ocrelizumab - drugs in development
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news